A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability,Pharmacokinetics, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

Trial Profile

A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability,Pharmacokinetics, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs MSB 0011359C (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors EMD Serono
  • Most Recent Events

    • 06 Jun 2017 Preliminary results (n=16) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2017 Planned End Date changed from 30 Nov 2018 to 12 Dec 2018.
    • 05 Jun 2017 Planned primary completion date changed from 28 Feb 2018 to 21 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top